GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

Two days after Monte Rosa Therapeutics Inc. signed a molecular glue degrader deal with Novartis AG, two other companies, ...

Neomorph will receive an upfront payment and may earn contingent milestone payments as the collaboration advances.

Bladder cancer is the ninth most common cancer globally, and the number of diagnosed incident cases is set to increase.

Needham analyst Ami Fadia has maintained their bullish stance on BIIB stock, giving a Buy rating yesterday. Ami Fadia has given her Buy rating ...

US biotech companies Biogen and Neomorph have announced a research collaboration to discover and develop molecular glue ...

Biogen touted strong Q3 sales of its Alzheimer’s drug Leqembi a day after announcing a deal worth up to $1.45 billion with ...

Biogen is the latest big biotech to make a play in protein degradation. The Massachusetts-based company has announced a deal to use Neomorph’s molecular glue degrader discovery platform to go after ...